Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL754497 | 0.87 | MAPK1 (0.36) | ALDH1A1MAPK1 | |
| SCHEMBL14890729 | 0.87 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL18892579 | 0.83 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL14890693 | 0.81 | MAPK1 (0.33) | MAPK1 | |
| SCHEMBL51026 | 0.80 | — | — | |
| SCHEMBL14891876 | 0.79 | — | — | |
| SCHEMBL19543667 | 0.79 | MAPK1 (0.32) | MAPK1 | |
| SCHEMBL17708256 | 0.79 | MAPK1 (0.32) | MAPK1 | |
| SCHEMBL16021743 | 0.78 | — | — | |
| SCHEMBL24742197 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4298182-B1 | DIELECTRIC THERMAL MANAGEMENT FLUIDS AND METHODS FOR USING THEM | CASTROL LTD (GB) | 2025-06-04 | — | — | EP | disclosed |
| US-20240191119-A1 | Dielectric Thermal Management Fluids and Methods for Using Them | CASTROL LIMITED (GB) | 2024-06-13 | — | — | US | disclosed |
| US-20220062273-A1 | CONJUGATES OF PATTERN RECOGNITION RECEPTOR AGONISTS | Ascendis Pharma Oncology Division A/S (DK) | 2022-03-03 | — | — | US | disclosed |
| US-20220054477-A1 | INDUCTION OF SUSTAINED LOCAL INFLAMMATION | Ascendis Pharma Oncology Division A/S (DK) | 2022-02-24 | — | — | US | disclosed |
| US-20210330798-A1 | TREATMENT OF INFECTIONS | ASCENDIS PHARMA A/S (DK) | 2021-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220054477-A1 | INDUCTION OF SUSTAINED LOCAL INFLAMMATION | GRPR, TLR3, TLR1 | ALDH1A1 3962/4885MAPK1 1581/4885 |
| US-20210330798-A1 | TREATMENT OF INFECTIONS | H1-10, PM20D2, ELANE | ALDH1A1 1667/4885MAPK1 2437/4885 |
| US-20220062273-A1 | CONJUGATES OF PATTERN RECOGNITION RECEPTOR AGONISTS | LPAR1, TACR1, ADGRF1 | ALDH1A1 1600/4885MAPK1 1185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.